MDxHealth SA has demonstrated strong topline growth, increasing revenues by nearly 20% year-over-year to $108 million in 2025 through the enhancement of its precision diagnostic test offerings for urologic diseases. This expansion is notably driven by acquisitions such as Exosome Diagnostics, which broadened its product portfolio with non-invasive assays like Exo mdx. Despite increasing sales and inclusion in clinical guidelines, MDxHealth remains unprofitable with a substantial accumulated deficit and ongoing cash burn. The company’s capital position is supported by recent equity raises and a $100 million loan facility, though repayment terms hinge on meeting revenue milestones. Watch for developments in reimbursement policies and successful integration of acquisitions as key determinants of MDxHealth’s path to sustainable profitability.